IL16 and lupus nephritis: Thus, as recently shown by Fava et al., a combination of urine biomarkers of intrarenal immunological activity (e.g., biomarkers of monocyte/neutrophil degranulation, macrophage activation, wound healing/matrix degradation, IL-16) would lead to a better characterization of proliferative lupus nephritis and prediction of clinical response [27].